Balchem is a defensively positioned specialty-ingredients compounder with 28 quarters of EBITDA growth, but its premium valuation demands sustained execution.
Overview
Balchem is a specialty ingredients compounder focused on proprietary, scientifically supported formulations rather than commodity chemicals. Its three segments serve resilient markets: HNH supplies infant formula, supplements, and food companies; ANH supplies livestock, feed, and pet markets; and SP supplies medical sterilization gases and plant micronutrients. The competitive position rests on formulation lock-in, regulatory validation, clinical evidence, and premium efficacy-in-use. Q2 2026 demonstrated operating resilience, with sales up 11.2% to $284.0 million, GAAP net earnings up 16.6% to $44.6 million, adjusted EBITDA up 12.6% to $77.9 million, and adjusted EPS up 17.3% to $1.49. The quarter marked the **28th consecutive quarter of year-over-year adjusted EBITDA growth** and beat consensus revenue by 5.77% and adjusted EPS by 19.2%. At $179.27 in mid-August 2026, valuation is demanding at 34.8x P/E, but is supported by approximately 36.9% year-to-date gross margins, 15.1% net margins, 97% free-cash-flow conversion, and minimal leverage. Catalysts include cognitive-choline clinical publication, Vitamin K2 expansion, European choline pricing recovery, and capacity investments.